The challenge of new drug discovery for tuberculosis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature

• Publication date

  2011-01-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/nature09657PMID 21270886
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The global plan to stop TB 2011-2015 : transforming the fight towards elimination of tuberculosis

  2011cited by this paper
• Biomarkers for tuberculosis disease activity, cure, and relapse.

  2010cited by this paper
• Letting sleeping dos lie: does dormancy play a role in tuberculosis?

  2010cited by this paper
• The Population Dynamics and Control of Tuberculosis

  2010cited by this paper
• Tuberculosis: What We Don’t Know Can, and Does, Hurt Us

  2010cited by this paper
• Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents

  2010cited by this paper
• New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades.

  2010cited by this paper
• Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis.

  2010cited by this paper
• Biomarkers for tuberculosis disease activity, cure, and relapse.

  2010cited by this paper
• An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis

  2010cited by this paper
• A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

  2010cited by this paper
• Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice

  2010cited by this paper
• Update on research and development pipeline: tuberculosis vaccines.

  2010cited by this paper
• Three Decades of β-Lactamase Inhibitors

  2010cited by this paper
• Respiratory ATP synthesis: the new generation of mycobacterial drug targets?

  2010cited by this paper
• Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of Tuberculosis

  2010cited by this paper
• Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.

  2010cited by this paper
• Linezolid in the treatment of multidrug-resistant tuberculosis.

  2010cited by this paper
• Tuberculosis 4 Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

  2010cited by this paper
• Global tuberculosis drug development pipeline: the need and the reality.

  2010cited by this paper
• Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

  2010cited by this paper
• Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?

  2009cited by this paper
• The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

  2009cited by this paper
• Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

  2009cited by this paper
• Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

  2009cited by this paper
• Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

  2009cited by this paper
• Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

  2009cited by this paper
• The role of the granuloma in expansion and dissemination of early tuberculous infection.

  2009cited by this paper
• Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes

  2009cited by this paper
• A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore

  2009cited by this paper
• The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

  2009cited by this paper
• Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India.

  2009cited by this paper
• The mechanism of action of PA-824

  2009cited by this paper
• Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

  2009cited by this paper
• Tuberculosis and diabetes mellitus: convergence of two epidemics.

  2009cited by this paper
• Antibiotics for Emerging Pathogens

  2009cited by this paper
• Mycobacterium tuberculosis and the macrophage: maintaining a balance.

  2008cited by this paper
• Physicochemical properties of antibacterial compounds: implications for drug discovery.

  2008cited by this paper
• A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

  2008cited by this paper
• Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis*

  2008cited by this paper
• The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

  2008cited by this paper
• Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

  2008cited by this paper
• Bacterial Growth and Cell Division: a Mycobacterial Perspective

  2008cited by this paper
• Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

  2008cited by this paper
• A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.

  2008cited by this paper
• Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents.

  2008cited by this paper
• The early bactericidal activity of anti-tuberculosis drugs: a literature review.

  2008cited by this paper
• The early bactericidal activity of anti-tuberculosis drugs : a literature review

  2008cited by this paper
• PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release

  2008cited by this paper
• Tuberculose et diabète

  2007cited by this paper
• [Tuberculosis and diabetes].

  2007cited by this paper
• Diarylquinolines target subunit c of mycobacterial ATP synthase.

  2007cited by this paper
• Drugs for bad bugs: confronting the challenges of antibacterial discovery

  2007cited by this paper
• Microbial phenotypic heterogeneity and antibiotic tolerance.

  2007cited by this paper
• The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Linezolid for the treatment of multidrug-resistant tuberculosis.

  2005cited by this paper
• Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration

  2005cited by this paper
• Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs.

  2005cited by this paper
• Tuberculosis — metabolism and respiration in the absence of growth

  2005cited by this paper
• Interplay between mycobacteria and host signalling pathways

  2004cited by this paper
• Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages

  2004cited by this paper
• Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

  2003cited by this paper
• Pharmacokinetic Interactions with Rifampicin

  2003cited by this paper
• Intrapulmonary Pharmacokinetics of Linezolid

  2002cited by this paper
• Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

  2001cited by this paper
• Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.

  1999cited by this paper
• The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module.

  1999cited by this paper
• Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• Erratum: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

  1995cited by this paper
• Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months.

  1993cited by this paper
• Aerial dissemination of pulmonary tuberculosis.

  1957cited by this paper
• Aerial dissemination of pulmonary tuberculosis.

  1957cited by this paper
• Tuberkulose und Diabetes

  1957cited by this paper
• Streptomycin in experimental tuberculosis: the effects in guinea pigs following infection in intravenous inoculation.

  1947cited by this paper

• Design, synthesis, and pharmacological profiling of benzimidazole-based isoniazid analogues: A comprehensive investigation into antitubercular activity, molecular characterization, and computational study

  2026cites this paper
• Contribution of Proteins to Membrane and Cell Wall Structures in Mycobacterium tuberculosis.

  2026cites this paper
• Design, synthesis, and molecular modeling of novel thiazolopyridine-based inhibitors of enoyl acyl carrier protein reductase (InhA) as anti-Mycobacterium tuberculosis agents.

  2026cites this paper
• Exploring antitubercular activity of new coumarin derivatives targeting enoyl acyl carrier protein reductase (InhA): Synthesis, biological evaluation and computational studies

  2025cites this paper
• Recent Developments in Structurally Diverse Anti-Tubercular Drug Molecules and Their Molecular Targets Against Mycobacterium tuberculosis

  2025cites this paper
• Click chemistry assisted synthesis of imidazo[1,2-a]pyrimidine-1,2,3-triazole hybrids as promising antitubercular agents: Design, characterization, in-vitro biological evaluation, molecular docking, DFT and in-silico ADME studies

  2025cites this paper
• Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis

  2025cites this paper
• Targeted and Controlled Drug Delivery Strategies for Overcoming Limitations of Conventional Tuberculosis Treatment: A Comprehensive Review

  2025cites this paper
• Microwave-assisted Green Synthesis: An Approach for the Development of Anti-tubercular Agents.

  2025cites this paper
• GATNM: Graph with Attention Neural Network Model for Mycobacterial Cell Wall Permeability of Drugs and Drug-like Compounds

  2025cites this paper
• Exploration of imidazothiazole and imidazopyrimidine carboxamides for enhanced antitubercular activity.

  2025cites this paper
• Inhibition of cytochrome bd oxidase in Mycobacterium tuberculosis by benzothiazole amides.

  2025cites this paper
• Cross-Talk Between Signal Transduction Systems and Metabolic Networks in Bacterial Antibiotics Resistance and Tolerance.

  2025cites this paper
• Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis

  2025cites this paper
• Integrated transcriptomic and metabolomic analyses reveal the antibacterial mechanism of isocorydine against Mycobacterium bovis

  2025cites this paper
• Resilience to stress and antibiotics, coupled with immunomodulatory behavior, uncovers Mycobacterium indicus pranii as a suitable surrogate model for tuberculosis research.

  2025cites this paper
• Discovery of novel inhibitors for malate synthase of Mycobacterium Tuberculosis from natural products.

  2025cites this paper
• Effective synthesis and anti-mycobacteriuml activity of isoxazole-substituted pyrrolopyrimidine and isoxazole-substituted indole derivatives

  2025cites this paper
• Discovery of ultra short β-peptoids with selective activity against drug-resistant Mycobacterium tuberculosis.

  2025cites this paper
• Hydrazineyl-linked imidazole[1,2-a]pyrimidine-thiazole hybrids: design, synthesis, and in vitro biological evaluation studies

  2025cites this paper
• Next generation tuberculosis therapy: from drug design to delivery

  2025cites this paper
• Pathogen-Specific Drug Metabolism in Tuberculosis: Enzymes, Metabolic Pathways, and New Horizons in Therapeutic Development.

  2025cites this paper
• Nanobots and Pharmacological Interventions: A Future Perspective on Eradicating Multidrug Resistant Tuberculosis

  2025cites this paper
• TCS-isatin-INH triads as potent and selective anti-mycobacterial with high efficacy against Mycobacterium tuberculosis

  2025cites this paper
• Utilizing artificial intelligence to predict and analyze socioeconomic, environmental, and healthcare factors driving tuberculosis globally

  2025cites this paper
• Mycobacterial phthiocerol dimycocerosate induces Galectin-3 upregulation to impair proinflammatory responses and favor immune evasion.

  2025cites this paper
• Efficacy of Xpert MTB/RIF assay in detecting Mycobacterium tuberculosis in samples with different results by smear and culture in a coastal city with high incidence of tuberculosis

  2025cites this paper
• Discovery of antitubercular potential of trans-3-indoleacrylic acid and its derivatives targeting Mycobacterium tuberculosis: A combined in vitro and in silico investigation.

  2025cites this paper
• Nanomaterials to Transform Infection Control with Antimicrobial Solutions

  2025cites this paper
• 1,3,4-oxadiazoles with effective anti-mycobacterial activity.

  2025cites this paper
• Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro

  2025cites this paper
• 11,12-dihydrolactaroviolin from edible mushroom Lactarius hatsudake Tanaka as a selective inhibitor of Mycobacterium tuberculosis.

  2025cites this paper
• Characterization of O-methyltransferase in Streptomyces sp. KCCM12257 and bioactivity assessment of polyphenols.

  2025cites this paper
• Understanding the key challenges in tuberculosis drug discovery: what does the future hold?

  2025cites this paper
• Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment

  2025cites this paper
• Antimycobacterial, antioxidative, anti-inflammatory, cytotoxic, anti-biofilm and synergistic interaction effects of five medicinal plants species used for tuberculosis infections in Sekhukhune, Limpopo, South Africa.

  2025cites this paper
• Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends

  2025cites this paper
• Potential of Mycobacterium tuberculosis Type II NADH-Dehydrogenase in Antitubercular Drug Discovery.

  2025cites this paper
• Development of tolerance to bedaquiline by overexpression of trypanosomal acetate: succinate CoA transferase in Mycobacterium smegmatis

  2025cites this paper
• Synthesis, Docking, and Biological Studies of Pyrazine Derivatives as Antimycobacterial Agents.

  2024cites this paper
• Nanoparticles Combining Host‐Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum

  2024cites this paper
• VIRTUAL DESIGN OF NOVEL OF ORALLY BIOAVAILABLE PIPERAZINE INHIBITORS OF ENOYL-ACYL CARRIER PROTEIN REDUCTASE OF MYCOBACTERIUM TUBERCULOSIS WITH FAVORABLE PHARMACOKINETIC PROFILES

  2024cites this paper
• Activity against Mycobacterium tuberculosis of a new class of spirooxindolopyrrolidine embedded chromanone hybrid heterocycles

  2024cites this paper
• Incidence and risk factors of active tuberculosis among older individuals with latent tuberculosis infection: a cohort study in two high-epidemic sites in eastern China

  2024cites this paper
• Long Dynamic β1–β2 Loops in M. tb MazF Toxins Affect the Interaction Modes and Strengths of the Toxin–Antitoxin Pairs

  2024cites this paper
• Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-d]pyrimidine-4, 7(3H, 8H)-dione Compounds.

  2024cites this paper
• Design, synthesis, and in silico studies of pyrazine-based derivatives as potential antitubercular agents

  2024cites this paper
• Synthesis and Structural Elucidation of Novel Quaternary Pyridinium Salt and Indolizine Derivatives as an Anti-tubercular Agent: In Silico and In Vitro Screening

  2024cites this paper
• Ionic liquid promoted facile one-pot synthesis of phenothiazine-thiazolidin-4-ones as potent antitubercular agents via mycobacterial ATP synthase inhibition

  2024cites this paper
• Design, synthesis, antiproliferative, antituberculosis and in-silico analysis of New Schiff base derivatives of cyclohepta[b]thiophene

  2024cites this paper
• Design, synthesis and computational studies of new azaheterocyclic coumarin derivatives as anti-Mycobacterium tuberculosis agents targeting enoyl acyl carrier protein reductase (InhA)

  2024cites this paper
• Exploring the binding mechanism and esterase-like activity of human serum albumin with levofloxacin and its choline based conjugates: A biophysical approach.

  2024cites this paper
• Activity-based protein profiling in drug/pesticide discovery: Recent advances in target identification of antibacterial compounds.

  2024cites this paper
• Metagenomics Analysis Reveals the Composition and Functional Differences of Fecal Microbiota in Wild, Farm, and Released Chinese Three-Keeled Pond Turtles (Mauremys reevesii)

  2024cites this paper
• Targeting decaprenylphosphoryl-β-D-ribose 2′-epimerase for Innovative Drug Development Against Mycobacterium Tuberculosis Drug-Resistant Strains

  2024cites this paper
• Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment

  2024cites this paper
• New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.

  2024cites this paper
• Combination Activity of Standard Antituberculosis Drugs and Extracts of Medicinal Plants Commonly Used in Traditional Treatment of Tuberculosis in Uganda

  2024cites this paper
• Human serum albumin directed formation of cadmium telluride quantum dots: Applications in biosensing, anti-bacterial activities and cell cytotoxicity measurements.

  2024cites this paper
• Study on the Anti-Mycobacterium marinum Activity of a Series of Marine-Derived 14-Membered Resorcylic Acid Lactone Derivatives

  2024cites this paper
• Virtual Screening Technique to Identify Inhibitors of Mycobacterium tuberculosis Rv3032 Protein Involved in MGLP Biosynthesis

  2024cites this paper
• Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase.

  2024cites this paper
• Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis.

  2024cites this paper
• Introducing a Toxicological Perspective to View Chemicals: A Web-Based Class for Educating Green Molecular Design

  2024cites this paper
• An intramolecular cross-talk in D29 mycobacteriophage endolysin governs the lytic cycle and phage-host population dynamics

  2024cites this paper
• Synthesis and Characterisation of Amino Functionalised Mesoporous Silica-based Nanomaterials for Isoniazid Drug Delivery

  2024cites this paper
• N-Acyl phenothiazines as mycobacterial ATP synthase inhibitors: Rational design, synthesis and in vitro evaluation against drug sensitive, RR and MDR-TB.

  2024cites this paper
• Gelatin Nanoparticles as Carrier for Effective Antituberculosis Drug Delivery in Combination Therapy

  2024cites this paper
• 2,3,5‐Trisubstituted Thiazolidinone Derivatives as Potential Antimicrobial and Antitubercular Agents and In Silico Studies

  2024cites this paper
• Knowledge Mapping of Drug Repositioning’s Theme and Development

  2023cites this paper
• Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets

  2023influential citation
• Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

  2023cites this paper
• Hydrazones tethered disubstituted 1,2,3-triazoles: design, synthesis, antitubercular and antimicrobial evaluation

  2023cites this paper
• Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal-Drug Synergism in Metallodrug Design.

  2023cites this paper
• In silico analysis to identify potential antitubercular molecules in Morus alba through virtual screening and molecular dynamics simulations

  2023cites this paper
• Synthesis, antitubercular evaluation, and molecular docking studies of hybrid pyridinium salts derived from isoniazid

  2023cites this paper
• Shikimate kinase inhibitors: An update on promising strategy against Mycobacterium tuberculosis.

  2023cites this paper
• Targeting mycobacterial membranes and membrane proteins: Progress and limitations.

  2023cites this paper
• Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.

  2023cites this paper
• Effective Synthesis and Anti‐Mycobacterial Activity of Isoxazole‐Substituted Piperazine Derivatives

  2023cites this paper
• Design, synthesis, molecular docking, and biological evaluation of coumarin‐thymidine analogs as potent anti‐TB agents

  2023cites this paper
• Synthesis of Novel 5‐Oxo‐1,2,4‐Oxadiazole Derivatives as Antitubercular Agents and Their Molecular Docking Study toward Enoyl Reductase (InhA) Enzyme

  2023cites this paper
• Characteristics of subtype III-A CRISPR-Cas system in Mycobacterium tuberculosis: An overview.

  2023cites this paper
• Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis

  2023cites this paper
• Synthesis and antituberculosis activity of new 5-alkynyl derivatives of 2-thiouridine: application of new scaffold

  2023cites this paper
• Novel 4,5-dibromo-N-phenyl-1H-pyrrole-2-carboxamide Hybrids as Promising DNA Gyrase Inhibitors: Design, Synthesis and Antimicrobial Evaluation

  2023cites this paper
• The Pharmacokinetics of CPZEN-45, a Novel Anti-Tuberculosis Drug, in Guinea Pigs

  2023cites this paper
• Synthesis and Antitubercular Activity of New 5-Alkynyl Derivatives of 2-Thiouridine

  2023cites this paper
• The oxidation of steroid derivatives by the CYP125A6 and CYP125A7 enzymes from Mycobacterium marinum.

  2023cites this paper
• Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization

  2023cites this paper
• Screening of Phytochemicals from Derris indica for Antimycobacterial Potential using Molecular Docking Analysis

  2023cites this paper
• Targeting Mycobacterium tuberculosis iron-scavenging tools: a recent update on siderophores inhibitors.

  2023cites this paper
• Isolation and characterization of a novel mycobacteriophage Kashi-VT1 infecting Mycobacterium species

  2023cites this paper
• Synthesis of novel furan-based chalcone derivatives as anti-tuberculosis agents: in vitro, cytotoxicity assessment and in silico.

  2023cites this paper
• Pyrrole: A Decisive Scaffold for the Development of Therapeutic Agents and Structure‐Activity Relationship

  2023cites this paper
• A mathematic equation derived from host-pathogen interactions elucidates the significance of integrating modern medicine with traditional Chinese medicine to treat infectious diseases.

  2023cites this paper
• Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli.

  2023cites this paper
• Design, synthesis and antitubercular assessment of 1, 2, 3-triazole incorporated thiazolylcarboxylate derivatives.

  2023cites this paper
• Recent advances in Fragment-based strategies against tuberculosis.

  2023cites this paper
• Crystal structure of the polyketide cyclase from Mycobacterium tuberculosis

  2022cites this paper